SFE Investment Counsel lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 2.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,244 shares of the company’s stock after selling 420 shares during the quarter. SFE Investment Counsel’s holdings in Johnson & Johnson were worth $2,923,000 at the end of the most recent reporting period.
A number of other large investors have also added to or reduced their stakes in the stock. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $35,000. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $40,000. TD Capital Management LLC acquired a new stake in shares of Johnson & Johnson in the 3rd quarter valued at $48,000. VitalStone Financial LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $52,000. Finally, Iron Horse Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 112.8% in the 4th quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares in the last quarter. Institutional investors and hedge funds own 67.94% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the company. StockNews.com assumed coverage on Johnson & Johnson in a research note on Thursday. They issued a “strong-buy” rating for the company. UBS Group assumed coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Morgan Stanley increased their price target on Johnson & Johnson from $179.00 to $183.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 19th. Piper Sandler dropped their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $173.00.
Johnson & Johnson Stock Performance
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, beating the consensus estimate of $2.51 by $0.17. The company had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a return on equity of 36.13% and a net margin of 13.22%. The firm’s revenue for the quarter was up 5.6% compared to the same quarter last year. During the same period last year, the business posted $2.67 EPS. On average, equities research analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.
Johnson & Johnson Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 6th. Stockholders of record on Tuesday, May 23rd will be paid a $1.19 dividend. The ex-dividend date is Monday, May 22nd. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 94.56%.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of Johnson & Johnson stock in a transaction dated Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Warren Buffett Boosts Occidental Stake, Adds 3.46 Million Shares
- What’s Behind The Recent Meteoric Rise Of Tingo Group
- Is PulteGroup Overbought After Double-Digit Gains?
- Netflix Stock Just Had Its Largest Intraday Gain Since 2022
- Analyst Flags Concerns About P&G Growth Despite Earnings Beat
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.